Αποτελέσματα Αναζήτησης
This protocol is part of the AC-TH regimen: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Link to Breast adjuvant AC-TH overview; Link to Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly; Drug status: Docetaxel is on the PBS general schedule. Trastuzumab is PBS authority
14 Δεκ 2023 · Other relevant topics, including principles of testing for HER2 expression on breast cancer tumor tissue, indications for neoadjuvant therapy versus adjuvant therapy in HER2-positive disease, and treatment protocols for HER2-positive disease are discussed elsewhere.
AC (Adriamycin® + Cyclophosphamide) followed by THP (Taxol® + Herceptin® + Pertuzumab) is a Chemotherapy Regimen for Breast Cancer - early stage. How does AC-THP work? Doxorubicin, cyclophosphamide, and paclitaxel are chemotherapy drugs designed to kill or slow the growth of cancer cells.
7 Δεκ 2022 · The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings.
(NCCN) guidelines and the St. Gallen International Expert Consensus support neoadjuvant systemic therapy for locally advanced HER2-positive breast cancer, along with surgery, radiation therapy, and (when appropriate) endocrine therapy.11,12 In this article, we review the best approaches to the treatment of locally advanced HER2-positive breast
EXCLUSIONS: Pregnancy. Significant cardiovascular disease and/or LVEF less than 50%; if initial reading is less than 50%, physician may consider repeating for validity, or assessing LVEF by the other modality, e.g. echocardiogram instead of MUGA. Known hypersensitivity to E. coli derived products.
25 Μαΐ 2020 · Abstract. Background: The optimal neoadjuvant treatment for HER2-positive breast cancer is unknown. We wanted to compare the efficacy and safety of the anthracycline regimen EC-TH versus nonanthracycline regimen TCH in neoadjuvant setting for HER2-positive breast cancer.
